Bristol-Myers Squibb (BMS) has reported strong third quarter results, announcing an 11% increase in revenue to $5.35bn attributed to the company’s blood thinning drug Plavix.
Plavix turnover rose 8% to $1.79bn, while the company also reported increases to its portfolio of HIV drugs, with Sustiva and Reyataz climbing 5% and 4% respectively.
BMS was, however, hit by a 29% fall in sales of Avapro/Avalide, used to treat hypertension.
CEO Lamberto Andreotti hailed the results and also praised data from the company’s trial of the stroke prevention medication Eliquis.
"We are excited by the strength of the Phase III data presented on Eliquis for stroke prevention in patients with atrial fibrillation and by the possibility that Eliquis could play a key role in the company’s future," he said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData